Equillium Company Insiders
| EQ Stock | USD 1.11 0.04 3.48% |
Equillium employs about 35 people. The company is managed by 14 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 2.5 employees per reported executive. Discussion of Equillium's management performance can provide insight into the enterprise performance.
| Daniel Bradbury Chairman Chairman of the Board, CEO |
Equillium | Build AI portfolio with Equillium Stock |
Equillium Management Team Effectiveness
The company has Return on Asset (ROA) of (0.4417) % which means that for every 100 dollars spent on asset, it generated a loss of $0.4417. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.9024) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities.Equillium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Equillium Workforce Comparison
Equillium is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 370. Equillium holds roughly 35.0 in number of employees claiming about 9% of equities under Health Care industry.
Equillium Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Equillium insiders, such as employees or executives, is commonly permitted as long as it does not rely on Equillium's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Equillium insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stephen Connelly 3 days ago Acquisition by Stephen Connelly of 90000 shares of Equillium at 0.785 subject to Rule 16b-3 | ||
Stephen Connelly over a week ago Acquisition by Stephen Connelly of 1025000 shares of Equillium at 1.74 subject to Rule 16b-3 | ||
Penny Tom over two weeks ago Disposition of 6533 shares by Penny Tom of Equillium at 1.29 subject to Rule 16b-3 | ||
Penny Tom over two weeks ago Acquisition by Penny Tom of 450000 shares of Equillium at 1.31 subject to Rule 16b-3 | ||
Zedelmayer Christine over a month ago Disposition of 23804 shares by Zedelmayer Christine of Equillium at 1.34 subject to Rule 16b-3 | ||
Zedelmayer Christine over a month ago Disposition of 7998 shares by Zedelmayer Christine of Equillium at 0.95 subject to Rule 16b-3 | ||
Stephen Connelly over two months ago Acquisition by Stephen Connelly of 175000 shares of Equillium at 0.785 subject to Rule 16b-3 | ||
Steel Bruce D. over six months ago Disposition of 245000 shares by Steel Bruce D. of Equillium at 5.03 subject to Rule 16b-3 |
Equillium Notable Stakeholders
An Equillium stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Equillium often face trade-offs trying to please all of them. Equillium's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Equillium's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Bruce Steel | CEO CoFounder | Profile | |
| Daniel Bradbury | Chairman of the Board, CEO | Profile | |
| Bruce CFA | President, CoFounder | Profile | |
| PMP MBA | Senior COO | Profile | |
| Stephen Connelly | Chief Scientific Officer, Director | Profile | |
| Jason Keyes | Chief Officer | Profile | |
| Penny Tom | Principal Officer | Profile | |
| Joel Rothman | Chief Officer | Profile | |
| Penny CPA | Senior Officer | Profile | |
| Matthew Ritter | Senior Development | Profile | |
| Maple MD | Chief Officer | Profile | |
| Krishna MD | Consultant | Profile | |
| Lisette Acevedo | Vice Development | Profile | |
| Michael Moore | Vice Communications | Profile |
About Equillium Management Performance
The success or failure of an entity such as Equillium often depends on how effective the management is. Equillium management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Equillium management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Equillium management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Equillium Workforce Analysis
Traditionally, organizations such as Equillium use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Equillium within its industry.Equillium Manpower Efficiency
Return on Equillium Manpower
| Revenue Per Employee | 1.2M | |
| Revenue Per Executive | 2.9M | |
| Net Loss Per Employee | 230.5K | |
| Net Loss Per Executive | 576.2K | |
| Working Capital Per Employee | 532.1K | |
| Working Capital Per Executive | 1.3M |
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.